Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review - PubMed (original) (raw)

Review

Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review

Marco Tuccori et al. Clin Ther. 2009 Jun.

Abstract

Background: There is ongoing debate about the safety of selective serotonin reuptake inhibitors (SSRIs) and other serotonergic/noradrenergic antidepressants when used during pregnancy.

Objective: This article reviews the available literature on the main safety concerns associated with the use of SSRIs and other serotonergic/noradrenergic antidepressants (serotonin-norepinephrine reuptake inhibitors, norepinephrine reuptake inhibitors, noradrenergic and specific serotonergic antidepressants) during pregnancy.

Methods: English-language reports of analytical and descriptive studies, including case reports, case series, and meta-analyses, were identified through searches of MEDLINE, EMBASE, and PsycINFO (1966-April 2009). The search terms were fluoxetine, paroxetine, sertraline, Citalopram, escitalopram, fluvoxamine, venlafaxine, mirtazapine, reboxetine, duloxetine, SSRI, SNRI, NaSSA, and NRI in association with depression, pregnancy, prenatal exposure, miscarriage, spontaneous abortion, malformation, in utero exposure, and neonatal complications.

Results: Paroxetine has been associated with significant risks of major malformation, particularly cardiac defects, when used during pregnancy. Significant associations between maternal exposure to SSRIs and both persistent pulmonary hypertension of the newborn and a self-limiting neonatal behavioral syndrome have been reported in a number of recent original studies and meta-analyses. Some studies have suggested a relationship between the use of SSRIs or other serotonergic/noradrenergic antidepressants and the occurrence of miscarriage, although these studies had methodologic limitations that affected the strength of the data. Evidence for a possible association between in utero exposure to SSRIs or other serotonergic/noradrenergic antidepressants and alterations in neurobehavioral development, bleeding, and QTc-interval prolongation is currently weak.

Conclusion: The available evidence suggests that SSRIs and other serotonergic/noradrenergic antidepressants should be used with caution during pregnancy, with careful follow-up of infants exposed to these agents in utero.

PubMed Disclaimer

Cited by

Maternal Psychiatric Conditions, Treatment With Selective Serotonin Reuptake Inhibitors, and Neurodevelopmental Disorders.
Ames JL, Ladd-Acosta C, Fallin MD, Qian Y, Schieve LA, DiGuiseppi C, Lee LC, Kasten EP, Zhou G, Pinto-Martin J, Howerton EM, Eaton CL, Croen LA. Ames JL, et al. Biol Psychiatry. 2021 Aug 15;90(4):253-262. doi: 10.1016/j.biopsych.2021.04.002. Epub 2021 Apr 14. Biol Psychiatry. 2021. PMID: 34116791 Free PMC article.
Cardiac Outcomes After Perinatal Sertraline Exposure in Mice.
Haskell SE, Lo C, Kent ME, Eggleston TM, Volk KA, Reinking BE, Roghair RD. Haskell SE, et al. J Cardiovasc Pharmacol. 2017 Aug;70(2):119-127. doi: 10.1097/FJC.0000000000000501. J Cardiovasc Pharmacol. 2017. PMID: 28459713 Free PMC article.
Bright light therapy in pregnant women with major depressive disorder: study protocol for a randomized, double-blind, controlled clinical trial.
Bais B, Kamperman AM, van der Zwaag MD, Dieleman GC, Harmsen van der Vliet-Torij HW, Bijma HH, Lieverse R, Hoogendijk WJ, Lambregtse-van den Berg MP. Bais B, et al. BMC Psychiatry. 2016 Nov 8;16(1):381. doi: 10.1186/s12888-016-1092-2. BMC Psychiatry. 2016. PMID: 27821114 Free PMC article. Clinical Trial.
Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.
Convertino I, Sansone AC, Marino A, Galiulo MT, Mantarro S, Antonioli L, Fornai M, Blandizzi C, Tuccori M. Convertino I, et al. Drug Saf. 2016 Oct;39(10):903-24. doi: 10.1007/s40264-016-0435-8. Drug Saf. 2016. PMID: 27289228 Review.
Constructing Causal Diagrams for Common Perinatal Outcomes: Benefits, Limitations and Motivating Examples with Maternal Antidepressant Use in Pregnancy.
Bandoli G, Palmsten K, Flores KF, Chambers CD. Bandoli G, et al. Paediatr Perinat Epidemiol. 2016 Sep;30(5):521-8. doi: 10.1111/ppe.12302. Epub 2016 May 10. Paediatr Perinat Epidemiol. 2016. PMID: 27160789 Free PMC article.

Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review - PubMed (original) (raw)